CCL3 and neuropathy: A blockade of the CCL3-CCL4-CCL5/CCR5 axis with maraviroc, a CCR5 antagonist, also reduces NP symptoms by inhibiting the expression of CCL3, CCL4 and CCL5 and intensifies morphine and buprenorphine analgesia in the CCI neuropathy model [249].